Total Payments
$1.7M
2024 Payments
$150,799
Companies
38
Transactions
2,337
Medicare Patients
4,801
Medicare Billing
$2.3M
Payment Breakdown by Category
Other$1.1M (65.2%)
Consulting$365,580 (21.2%)
Travel$192,039 (11.1%)
Food & Beverage$42,370 (2.5%)
Education$512.25 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 535 | 64.8% |
| Consulting Fee | $365,580 | 126 | 21.2% |
| Travel and Lodging | $192,039 | 668 | 11.1% |
| Food and Beverage | $42,370 | 989 | 2.5% |
| Honoraria | $6,650 | 3 | 0.4% |
| Education | $512.25 | 15 | 0.0% |
| Unspecified | $0 | 1 | 0.0% |
Payments by Type
General
$1.7M
2,336 transactions
Ownership
$0
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $343,952 | 276 | $0 (2024) |
| Lilly USA, LLC | $230,373 | 399 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $207,765 | 262 | $0 (2019) |
| ABBVIE INC. | $201,560 | 331 | $0 (2024) |
| Amgen Inc. | $137,878 | 230 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $107,168 | 105 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $93,330 | 113 | $0 (2024) |
| GlaxoSmithKline, LLC. | $64,554 | 74 | $0 (2024) |
| PFIZER INC. | $61,886 | 132 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $61,019 | 85 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $150,799 | 175 | GENZYME CORPORATION ($67,306) |
| 2023 | $155,744 | 232 | ABBVIE INC. ($57,879) |
| 2022 | $184,381 | 276 | AstraZeneca Pharmaceuticals LP ($37,241) |
| 2021 | $140,297 | 154 | AbbVie Inc. ($31,962) |
| 2020 | $141,595 | 177 | Lilly USA, LLC ($32,138) |
| 2019 | $335,476 | 464 | GENZYME CORPORATION ($64,172) |
| 2018 | $353,953 | 482 | Regeneron Healthcare Solutions, Inc. ($106,903) |
| 2017 | $261,892 | 377 | GENZYME CORPORATION ($72,891) |
All Payment Transactions
2,337 individual payment records from CMS Open Payments — Page 1 of 94
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/23/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,565.00 | General |
| Category: Immunology | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $12.99 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $23.71 | General |
| Category: Immunology | ||||||
| 12/05/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $0.89 | General |
| Category: Immunology | ||||||
| 11/25/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/21/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $6.50 | General |
| Category: IMMUNOLOGY | ||||||
| 11/18/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $37.12 | General |
| Category: IMMUNOLOGY | ||||||
| 11/15/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| 11/15/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $59.84 | General |
| Category: IMMUNOLOGY | ||||||
| 11/15/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $26.65 | General |
| Category: Rheumatology | ||||||
| 11/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $11.48 | General |
| Category: Inflammation | ||||||
| 10/23/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $325.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/21/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,268.00 | General |
| Category: Rheumatology | ||||||
| 10/21/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,180.00 | General |
| Category: Rheumatology | ||||||
| 10/21/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Travel and Lodging | In-kind items and services | $836.94 | General |
| Category: Rheumatology | ||||||
| 10/21/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Travel and Lodging | In-kind items and services | $751.77 | General |
| Category: Rheumatology | ||||||
| 10/21/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Travel and Lodging | In-kind items and services | $362.30 | General |
| Category: Rheumatology | ||||||
| 10/21/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Travel and Lodging | Cash or cash equivalent | $160.00 | General |
| Category: Rheumatology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,251 | 46,217 | $1.7M | $654,387 |
| 2022 | 16 | 1,225 | 33,140 | $1.4M | $562,263 |
| 2021 | 19 | 1,248 | 31,530 | $1.4M | $577,255 |
| 2020 | 17 | 1,077 | 27,718 | $1.2M | $527,440 |
Total Patients
4,801
Total Services
138,605
Medicare Billing
$2.3M
Procedure Codes
69
All Medicare Procedures & Services
69 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 23 | 19,126 | $763,680 | $201,869 | 26.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 95 | 9,780 | $264,060 | $180,777 | 68.5% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 14 | 14,700 | $352,800 | $115,975 | 32.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 437 | 1,118 | $167,700 | $107,842 | 64.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 35 | 195 | $58,500 | $20,826 | 35.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 61 | 61 | $16,775 | $7,068 | 42.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 28 | 79 | $23,700 | $4,195 | 17.7% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 52 | 71 | $14,200 | $3,814 | 26.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 239 | 449 | $4,295 | $3,635 | 84.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 104 | 315 | $31,500 | $3,484 | 11.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 15 | $3,000 | $2,271 | 75.7% |
| 20550 | Injection into tendon or ligament | Office | 2023 | 16 | 19 | $3,800 | $778.90 | 20.5% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 22 | 110 | $35,200 | $705.41 | 2.0% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 67 | 104 | $2,080 | $566.62 | 27.2% |
| 85810 | Blood viscosity measurement | Office | 2023 | 15 | 25 | $625.00 | $285.96 | 45.8% |
| 89060 | Crystal identification from tissue or body fluid | Office | 2023 | 15 | 25 | $625.00 | $179.54 | 28.7% |
| 89050 | Body fluid cell count | Office | 2023 | 15 | 25 | $625.00 | $115.71 | 18.5% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 25 | 20,650 | $826,000 | $244,465 | 29.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 100 | 10,020 | $270,540 | $171,682 | 63.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 414 | 1,089 | $163,350 | $104,550 | 64.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 38 | 142 | $42,600 | $16,935 | 39.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 58 | 58 | $15,950 | $7,366 | 46.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 48 | 117 | $35,100 | $6,345 | 18.1% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 40 | 50 | $10,000 | $2,901 | 29.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 100 | 237 | $23,700 | $2,747 | 11.6% |
About Dr. Alan Epstein, M.D
Dr. Alan Epstein, M.D is a Rheumatology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346211844.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alan Epstein, M.D has received a total of $1.7M in payments from pharmaceutical and medical device companies, with $150,799 received in 2024. These payments were reported across 2,337 transactions from 38 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.1M).
As a Medicare-enrolled provider, Epstein has provided services to 4,801 Medicare beneficiaries, totaling 138,605 services with total Medicare billing of $2.3M. Data is available for 4 years (2020–2023), covering 69 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Philadelphia, PA
- Active Since 02/01/2006
- Last Updated 06/17/2022
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1346211844
Products in Payments
- KEVZARA (Drug) $209,445
- KEVZARA (Biological) $169,211
- KEVZARA SARILUMAB INJECTION (Biological) $150,113
- TALTZ (Drug) $130,709
- RINVOQ (Biological) $93,306
- SAPHNELO (Biological) $76,170
- Prolia (Biological) $66,809
- XELJANZ (Drug) $57,350
- SIMPONI ARIA (Biological) $56,589
- BENLYSTA (Biological) $56,053
- COSENTYX (Biological) $50,535
- STELARA (Biological) $50,369
- TREMFYA (Drug) $41,257
- SKYRIZI (Biological) $34,125
- ORENCIA (Biological) $27,610
- Humira (Biological) $23,266
- Otezla (Drug) $22,843
- OLUMIANT (Drug) $18,625
- EVENITY (Biological) $18,089
- Rinvoq (Biological) $10,741
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Philadelphia
Alexis Ogdie-Beatty, Md, MD
Rheumatology — Payments: $543,413
Rheumatology $543,413
Lawrence Brent, Md, MD
Rheumatology — Payments: $26,698
Rheumatology $26,698
Dr. Bruce Hoffman
Rheumatology — Payments: $23,015
Rheumatology $23,015
Ethan Craig, Md, MD
Rheumatology — Payments: $20,704
Rheumatology $20,704
Monica Luchi, Md, MD
Rheumatology — Payments: $20,434
Rheumatology $20,434
Dr. Jill Johnson, M.d, M.D
Rheumatology — Payments: $15,757
Rheumatology $15,757